Tropisetron (Navoban) in the control of nausea and vomiting induced by combined cancer chemotherapy in children.
Open Access
- 1 February 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 29 (2), 92-95
- https://doi.org/10.1093/jjco/29.2.92
Abstract
Background: We aimed to assess the potency and efficacy of tropisetron, a 5-HT3 receptor antagonist, in the prevention of nausea and emesis observed in the pediatric patient population taking various chemotherapy protocols. Methods: Tropisetron (Navoban®) was given to 100 children (62 boys and 38 girls aged 6 months to 15 years) with various malignancies. Patients received tropisetron during one or more courses of emetogenic chemotherapy for a total of 350 courses administered intravenously or intravenously and intrathecally. Tropisetron (0.2 mg/kg/day, maximum: 5 mg/day) was administered as a single intravenous dose slowly, before the start of chemotherapy on day 1 and intravenously or by mouth on subsequent days (median treatment duration: 5 days). Results: The patients receiving cytotoxic chemotherapy had a 70% complete response rate and a 24% partial response rate during the first 24 h period of the first course. We observed headache (five courses), diarrhea (three courses) and loss of appetite (one course) as side-effects (2.5%). Conclusion: Tropisetron is safe, effective, easy to use, has no serious side-effects and can be recommended for pediatric patients. The efficacy of tropisetron may be enhanced by the addition of corticosteroids in patients receiving highly emetogenic cancer chemotherapy.Keywords
This publication has 10 references indexed in Scilit:
- Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapyMedical and Pediatric Oncology, 1995
- Randomized Double-Blind Crossover Ondansetron-Dexamethasone versus Ondansetron-Placebo Study for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients with MalignanciesJournal of Pediatric Hematology/Oncology, 1995
- Optimal combination therapy with Navoban® (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomitingAnti-Cancer Drugs, 1995
- Safety, tolerability, efficacy and plasma concentrations of tropisetron after administration at five dose levels to children receiving cancer chemotherapyEuropean Journal of Cancer, 1994
- Prevention of emesis by ics 205-930 in children receiving cytotoxic chemotherapyEuropean Journal of Cancer, 1993
- Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: The Nordic experienceAnnals of Oncology, 1993
- Nobel's day on recent advances in cancer researchAnnals of Oncology, 1993
- Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapyThe Lancet, 1991
- Neuropharmacology of emesis induced by anti-cancer therapyTrends in Pharmacological Sciences, 1988
- Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugsNature, 1985